Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Exelixis (EXEL) PT Raised to $33 at Needham & Company
February 13, 2019 10:52 AM ESTNeedham & Company analyst Chad Messer raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $30.00) while maintaining a Buy rating.
Messer commented, "Exelixis reported $176M in Cabo sales in 4Q:18, an 8% increase q/q. FY18 Cabo sales were $619M, a 44% increase... More
Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q
February 13, 2019 10:01 AM ESTGuggenheim analyst Michael Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $31.00) while maintaining a Buy rating following the company's 4Q earnings report. EXEL reported 4Q18 revenue of $229M, 22% above Street consensus of $188M. Non-GAAP diluted EPS was 0.37, driven mostly by a... More
Exelixis (EXEL) PT Lowered to $31 at Oppenheimer
February 13, 2019 7:58 AM ESTOppenheimer analyst Silvan Tuerkcan lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $40.00) while maintaining a Outperform rating.
The analyst commented, "EXEL reported 4Q $176.2M revenue beating $170.0M consensus driven by Cabometyx sales of $171.6M vs $166M consensus. Cabometyx sales grew... More
Exelixis (EXEL) Tops Q4 EPS by 13c
February 12, 2019 4:07 PM ESTExelixis (NASDAQ: EXEL) reported Q4 EPS of $0.37, $0.13 better than the analyst estimate of $0.24. Revenue for the quarter came in at $228.6 million versus the consensus estimate of $188.76 million.
2019 Financial Guidance
The company is providing the following financial guidance for 2019. Cost of goods... More
